Therapiesteuerung der COPD durch eosinophile Granulozyten?

Abstract

Symptomatic patients with COPD reporting about repeated exacerbations in their history (group D according to GOLD recommendations) are treated with dual bronchodilation (LAMA/LABA) with potential benefits from additional ICS. Eosinophils in peripheral blood are considered as potential biomarkers to predict exacerbations. > 300 cells/µL or 4 % of eosinophils in peripheral blood are recommended to treat the patients with additional ICS. In clinical practice, about 10 – 15 % of patients with COPD are classified as group D according to GOLD. < 20 % have increased eosinophils in peripheral blood. Thus, ICS therapy should be restricted to a minority of patients with COPD

Schwerpunkt der medikamentösen Therapie der symptomatischen COPD sind langwirksame Anticholinergika (LAMA) und langwirksame β₂-Symphatikomimetika (LABA). Zusätzlich können bei symptomatischen Patienten mit gehäuften Exazerbationen inhalative Kortikosteroide hilfreich sein. Welche Patienten darauf ansprechen, lässt sich möglicherweise mithilfe einer erhöhten Eosinophilen-Zahl im peripheren Blut vorhersagen.

Schlüsselwörter

COPD - inhalative Kortikosteroide (ICS) - eosinophile Granulozyten

Key words

COPD - inhaled corticosteroids - eosinophils

• Literatur

• 1 Vogelmeier C, Buhl R, Burghuber O. et al. Guideline for the Diagnosis and Treatment of COPD Patients – Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology. Pneumologie 2018; 72: 253-308
• 2 Vogelmeier C, Criner GJ, Martinez FJ. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Am J Respir Crit Care Med 2017; 195: 557-582
• 3 Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.5-FINAL-04Nov2018_WMS.pdf . Accessed February 28, 2019.
• 4 Graf J, Jörres R, Lucke T. et al. Medikamentöse Therapie der COPD. Deutsches Ärzteblatt 2018; 37: 599-605
• 5 Calverley P, Anderson J, Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 22: 775-789
• 6 Wedzicha J, Calverley P, Seemungal T. et al. The prevention of Chronic Obstructive Pulmonary Disease exacerbations by Salmeterol/Fluticasone propionate or Tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26
• 7 Suissa S, Patenaude V, Lapi F. et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036
• 8 Brusselle G, Pavord I, Landis S. et al. Blood eosinophil levels as a biomarker in COPD. Respir Med 2018; 138: 21-31
• 9 Agusti A, Fabbri L, Singh D. et al. Inhaled corticosteroids in COPD: Friend or foe?. Eur Respir J 2018;
• 10 Papi A, Vestbo J, Fabbri L. et al. Extrafine inhaled Tripel therapy versus dual bronchodilator therapy in Chronic Obstructive Pulmonary Disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076-1084
• 11 Lipson D, Barnhart F, Brealey N. et al. Once-daily single inhaler Tripel versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671-1680
• 12 Magnussen H, Disse B, Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294
• 13 Chapman K, Hurst J, Frent S. et al. Long-Term Tripel Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Tripel-Dummy Clinical Trial. Am J Respir Crit Care Med 2018; 198: 329-339
• 14 Wedzicha J, Banerji D, Chapman K. et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374: 2222-2234
• 15 Watz H, Tetzlaff K, Wouters EF. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4: 390-398
• 16 Calverley P, Tetzlaff K, Vogelmeier C. et al. Eosinophilia, frequent exacerbations, and steroid response in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2017; 196: 1219-1221
• 17 Buhl R, Criée C, Kardos P. et al. Dual bronchodilation vs Tripel therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis 2018; 13: 2557-2558
• 18 Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med 2018; 6: 855-862
• 19 Yun J, Lamb A, Chase R. et al. Blood eosinophil count thresholds and exacerbations in patients with Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol 2018; 141: 2037-2047
• 20 Brusselle G, Price D, Gruffydd-Jones K. et al. The inevitable drift to Tripel therapy in COPD: an analysis of prescribing pathways in the UK. International Journal of COPD 2015; 10: 2207-2217